GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
ViiV Healthcare announces positive data demonstrating long-acting injectable Cabenuva (cabotegravir, rilpivirine) is as effective as daily oral Biktarvy (BIC/FTC/TAF) for the treatment of HIV-1

For media and investors only- 12-month findings from the SOLAR study showed that the every-two-month regimen of CAB+RPV LA demonstrated non-inferior efficacy compared to continuation of... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
Landmark New England Journal of Medicine publication reinforces potential of GSK’s respiratory syncytial virus older adult vaccine candidate

For media and investors only- First peer-reviewed publication of phase III respiratory syncytial virus vaccine data in older adults, including those with comorbidities who are most at r... Read More
GSK
2 years ago ⋅ English ⋅ 19 min read
Newsroom
ViiV Healthcare to present first head-to-head data for long-acting HIV treatment Cabenuva against daily oral Biktarvy at CROI 2023

For media and investors onlyOther key data to be presented from ViiV Healthcare’s innovative pipeline and portfolio include new HIV prevention findings for long-acting cabotegravi... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
US FDA grants regular approval for Jemperli for the treatment of patients with recurrent or advanced mismatch repair-deficient endometrial cancer

For media and investors only- Conversion from accelerated to regular (full) approval based on long-term outcomes from the GARNET phase I trial, which demonstrated an overall response ra... Read More
GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
US FDA Advisory Committee votes in support of trials designed to evaluate Jemperli (dostarlimab-gxly) as a potential treatment for mismatch repair-deficient/microsatellite instability-high locally advanced rectal cancer

For media and investors only- US FDA also recently granted Fast Track designation to Jemperli in this patient populationGSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
GSK announces results from 17-year retrospective study on US clinical trial diversity

For media and investors only- Study published today in Clinical Trials: Journal of the Society for Clinical Trials examined clinical trial diversity across 495 GSK trials involving over... Read More